REVEAL Registry PAH Risk Score Calculator

Slides:

Advertisements

Similar presentations

Pulmonary hypertension Goal directed therapy Pulmonary Hypertension Programme University of Toronto FMD.

Advertisements

Picture of my family – love to start talks in the comfort of my living room. Feel passionate about my girls and about this unique population of patients.

Epidermal growth factor receptor (EGFR) mutations in NSCLC

Reproduced with permission from Albert MA, Ridker PM

Management of mitral regurgitation. See legend for Fig

Adapted from Weiss et al. J Am Coll Cardiol. 1998;31:

Hemodynamic classification of pulmonary hypertension (PH)

Causes of Pulmonary Hypertension in the Elderly

Recommended algorithm for perioperative management of patients with pulmonary arterial hypertension (PAH) secondary to congenital heart disease (CHD) in.

Clinical factors increasing index of suspicion for tuberculosis

Organizing pneumonia (OP)

T cell differentiation

Correlation between pulmonary arterial pulse pressure (PP) measured using fluid-filled Swan–Ganz (SG) versus high-fidelity micromanometer-tipped Millar.

The Canadian Hypertension Education Program expedited assessment and diagnosis of patients with hypertension: Focus on validated technologies for blood.

Criteria used to determine breath types during mechanical ventilation

Diaphragmatic length–tension curve in normal hamsters and hamsters with elastase-induced emphysema. Tension is expressed as a percentage of maximum tetanic.

Echocardiographic modalities for evaluation and risk stratification of heart failure patients. 3D indicates 3-dimensional; EF, ejection fraction; LA, left.

Kaplan-Meier survival for adult heart transplants performed between January 1982 and June 2006 by era. All comparisons are significant at p < (Reproduced.

(Reproduced with permission from Amato AA, Russell JA

(Adapted and reprinted with permission, from Hughes JM et al: Effect of lung volume on the distribution of pulmonary blood flow in man. Respir Physiol.

Pulmonary arterial hypertension due to pulmonary veno-occlusive disease in systemic sclerosis: Importance of early diagnosis and cautious use of pulmonary.

Fungal histopathology. A. India ink wet mount C. neoformans. B

Adapted with permission from Hsia, J et al

Volumetric reconstruction of axial magnetic resonance (MR) images in a normal subject (top panel) and a patient with sleep apnea (bottom panel). The mandible.

Posteroanterior chest x-ray film in a man with acute pulmonary edema resulting from left ventricular failure. Note the bat’s wing density, cardiac enlargement,

Chest radiograph cardiac enlargement, with prominence of the pulmonary artery, right atrium, and right ventricle, in a patient with primary pulmonary hypertension.

Guideline for approaching the differential diagnosis of pulmonary hypertension. CHD, congenital heart disease; CO, cardiac output; CT, contrast-enhanced.

The Hippocrates of Ostia

Volume 141, Issue 2, Pages (February 2012)

by Victor R. Gordeuk, Oswaldo L. Castro, and Roberto F. Machado

Are Direct Oral Anticoagulants Appropriate for PAH?

Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL.

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

Brian P. Shapiro, MD, Horng H. Chen, MD, John C

ECG: electrocardiogram; PFT: pulmonary function testing; Dlco: diffusion capacity of the lung for carbon monoxide; BGA: blood gas analysis; HRCT: high-resolution.

Five-Year Outcomes of Patients Enrolled in the REVEAL Registry

Cohort identification and exclusion.

Volume 146, Issue 6, Pages (December 2014)

Volume 146, Issue 5, Pages (November 2014)

Algorithm for the diagnosis and treatment of portopulmonary hypertension (POPH). Algorithm for the diagnosis and treatment of portopulmonary hypertension.

REVEAL pulmonary arterial hypertension (PAH) risk score.

Michael D. McGoon, MD, Abby Krichman, RRT, Harrison W

Cox proportional hazard estimates for multivariate model of survival, limited to terms included in the final stepwise model. Cox proportional hazard estimates.

Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.

An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.

An expert proposal for a treat-to-target checklist for pulmonary arterial hypertension (PAH). An expert proposal for a treat-to-target checklist for pulmonary.

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Selection of patients: 248 consecutive patients with newly diagnosed pre-capillary pulmonary hypertension were included in the study. Selection of patients:

Patient case study 2—fibrotic uILD in the setting of IPAF

Micha T. Maeder, MD, PhD, Niklas F. Ehl, MD

Simplified REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) risk score. Simplified REVEAL (Registry to Evaluate Early And Long-term.

Proposed screening algorithm for identification of pulmonary arterial hypertension (PAH) associated with connective tissue disease. Proposed screening.

Predicting Survival in Patients With Pulmonary Arterial Hypertension

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

When we compared cardiac volumes (ED and ES) between those with high BNP levels (BNP >400 pg/mL) and low BNP (

Volume 133, Issue 4, Pages (April 2008)

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

How to Screen for PAH in Scleroderma-Spectrum Disorders

Distribution of mutations in sporadic and familial pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary.

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

Results of classification and regression tree analysis in patients with pulmonary hypertension-sickle cell disease. Results of classification and regression.

Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.

A) Pulmonary arterial hypertension (PAH) aetiological breakdown of REVEAL patients at enrolment. b) Breakdown of associated PAH subgroup. a) Pulmonary.

Algorithm for haemodynamic evaluation in the elderly.

Distribution of diffusing capacity of the lung for carbon monoxide (DLCO) among 243 scleroderma patients who underwent right heart catheterisation (RHC)

Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort. Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort.

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Overall survival in all cases.

Schematic diagram of the DETECT study [56].

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

REVEAL Registry PAH Risk Score Calculator REVEAL Registry PAH Risk Score Calculator. Calculated risk scores can range from 0 (lowest risk) to 22 (highest risk). In the REVEAL cohort, the average predicted 1-year survival was 95% to 100% in the low-risk group (score <7), 90% to <95% in the average-risk group (score 8), 85% to <90% in the moderately high-risk group (score 9), 70% to <85% in the high-risk group (score 10–11), and 12). If N-terminal proBNP is available and BNP is not, listed cut points are replaced with 1500 pg/mL. APAH, associated pulmonary arterial hypertension; BNP, brain natriuretic peptide; BPM, beats per minute; CTD, connective tissue disease; Dlco, diffusing capacity of lung for carbon monoxide; FPAH, familial pulmonary arterial hypertension; HR, heart rate; mRAP, mean right atrial pressure; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PoPH, portopulmonary hypertension; PVR, pulmonary vascular resistance; REVEAL Registry, Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management; SBP 5 systolic BP; WHO, World Health Organization. (Reproduced with permission from Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141(2):354–362.) Source: Pulmonary Arterial Hypertension, Fishman's Pulmonary Diseases and Disorders, 5e Citation: Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM, Siegel MD. Fishman's Pulmonary Diseases and Disorders, 5e; 2015 Available at: https://accessmedicine.mhmedical.com/DownloadImage.aspx?image=/data/Books/1344/p9780071796729-ch072_f011.png&sec=111836043&BookID=1344&ChapterSecID=81192445&imagename= Accessed: November 22, 2017 Copyright © 2017 McGraw-Hill Education. All rights reserved